Ablation devices market seen rising to $24.67 billion by 2035

Market Research Future projects the global ablation devices market will grow from $9.49 billion in 2026 to $24.67 billion by 2035, driven by minimally invasive procedures, rising arrhythmia cases and pulsed-field ablation. North America leads now, while Asia-Pacific is set to grow the fastest as hospitals expand interventional capacity.

Why it matters: - Ablation devices are moving deeper into routine care across cardiology, oncology, gastroenterology, urology and other specialties. - The market’s projected growth signals broader demand for procedures that can reduce recovery time, support outpatient care and expand treatment options for hard-to-treat disease. - The forecast also points to a bigger shift toward image-guided, catheter-based and energy-delivery technologies in hospital systems worldwide.

What happened: - Market Research Future said the global ablation devices market reached $8.53 billion in 2025. - The market is projected to rise from $9.49 billion in 2026 to $24.67 billion by 2035. - That forecast implies an 11.20% compound annual growth rate from 2026 to 2035. - The report ties growth to adoption of minimally invasive procedures and next-generation technologies. - Request a free sample of the report.

The details: - Rising atrial fibrillation and other cardiac arrhythmias are expanding demand for cardiac ablation. - Reimbursement gains in markets including Germany and Japan are supporting more interventional treatment. - Pulsed-field ablation is drawing attention because it uses a non-thermal mechanism designed to target cardiac tissue while limiting damage to nearby structures. - Hospital modernization in China, India and Southeast Asia is opening new adoption opportunities. - Cancer incidence is also lifting demand for tumor ablation, especially for hepatocellular carcinoma, renal cell carcinoma and pulmonary metastases. - Combination use of ablation and immunotherapy is creating another path for device adoption. - Radiofrequency technology held the largest device share in 2025 at 46.3%. - Cryoablation accounted for 18.7% of revenue in 2025. - Ultrasound devices represented 12.4% of the market in 2025. - Pulsed-field ablation held 8.9% of revenue in 2025 and is expected to be the fastest-expanding technology through 2035. - Oncology was the largest application segment in 2025 with a 42.1% revenue share. - Cardiovascular disease is the fastest-growing application and is projected to post a 12.90% CAGR from 2026 to 2035. - Ophthalmology was valued at $0.68 billion in 2025. - Hospitals and clinics were the largest end-user segment in 2025 with a 69.1% share. - Ambulatory surgical centers are expected to be the fastest-growing end-user segment, with a projected 13.75% CAGR. - Percutaneous procedures led the market in 2025 with a 63.8% share. - Laparoscopic procedures are forecast to grow at a 12.30% CAGR from 2026 to 2035. - North America held about 41.3% of the global market in 2025. - The United States accounted for 76.8% of North American revenue. - Europe held about 27.5% of the global market in 2025. - Asia-Pacific is the fastest-growing region, with a projected 13.05% CAGR from 2026 to 2035. - India is projected to grow at a 14.20% CAGR. - South America held about 5.2% of the market in 2025. - The Middle East and Africa held about 4.2% of the market in 2025. - The market is moderately concentrated, with the top five players accounting for about 55% to 62% of global sales. - Medtronic, Johnson & Johnson’s Biosense Webster, Boston Scientific, Abbott, AngioDynamics and Stryker are among the named competitors.

Between the lines: - The forecast suggests the biggest gains will come from technologies that improve precision, shorten procedures and support more outpatient care. - Pulsed-field ablation appears positioned as the most important technology transition because it combines safety claims, speed and strong cardiology demand. - Asia-Pacific’s growth trajectory suggests the next wave of volume may come from infrastructure buildout rather than only from mature U.S. and European hospital networks. - The report’s emphasis on AI-assisted imaging and catheter navigation hints that software may become as important as hardware in future purchasing decisions.

What's next: - AI-driven procedural autonomy could reshape workflow by improving lesion assessment, catheter steering and complication alerts. - Semi-autonomous systems may start shortening procedures and reducing the training burden for operators by 2030. - Single-use ablation platforms are likely to gain more traction as providers look to reduce reprocessing and infection-related concerns. - Manufacturers may increasingly lean on consumables, service contracts and software subscriptions for revenue growth.

The bottom line: - Ablation devices are shifting from niche procedural tools to a broad growth market built on minimally invasive care, new energy-delivery systems and expanding hospital capacity.